Glucotrack Seeks Shareholder Approval for Highly Dilutive Capital Raises Critical for Survival

summarizeSummary

Glucotrack, Inc. filed a definitive proxy statement seeking shareholder approval for two highly dilutive capital raises, including an Equity Line of Credit and warrant exercises, which are crucial for the company's continued operations and explicitly linked to avoiding potential liquidation.

check_boxKey Events

• Shareholder Vote on Highly Dilutive ELOC

  The company seeks approval for an Equity Line of Credit (ELOC) with Sixth Borough Capital Fund, LP, allowing it to issue shares representing over 670% of its pre-agreement outstanding common stock to raise up to $20 million. This follows the S-3 registration filed on 2026-01-13 and the preliminary proxy statement on 2026-01-29.

• Approval Sought for Massively Dilutive Warrant Exercise

  Shareholders will vote on approving the issuance of shares upon the exercise of 2,067,182 common warrants held by Armistice Capital Master Fund Ltd. If approved, the investor could own approximately 77% of the company's post-issuance common stock, providing up to an additional $8 million. The company warns that failure to approve could lead to liquidation or bankruptcy.

• Auditor Ratification Follows Prior Disclosure of Going Concern

  The filing includes a proposal to ratify the appointment of CBIZ CPAs P.C. as the independent auditor for 2025. This follows the dismissal of previous auditor Grant Thornton in July 2025, which had previously issued reports with a 'going concern' explanatory paragraph and noted material weaknesses in internal controls, as disclosed in an 8-K on 2025-07-24.

auto_awesomeAnalysis

Glucotrack, Inc. has filed a definitive proxy statement to finalize shareholder approval for two critical and highly dilutive capital raises, previously outlined in a preliminary filing. The first proposal seeks approval for an Equity Line of Credit (ELOC) with Sixth Borough Capital Fund, LP, potentially allowing the company to issue shares representing over 670% of its pre-agreement outstanding common stock to raise up to $20 million. The second proposal requests approval for the issuance of shares upon the exercise of over 2 million common warrants held by Armistice Capital Master Fund Ltd., which could result in the investor owning approximately 77% of the company's post-issuance common stock and provide up to an additional $8 million. The company explicitly warns that failure to approve the warrant exercise could jeopardize its ability to execute its business plan, potentially leading to liquidation or bankruptcy. These capital raises are substantial relative to the company's current valuation, indicating a critical need for funding. The filing also includes a routine proposal to ratify the appointment of CBIZ CPAs P.C. as the independent auditor, following the dismissal of Grant Thornton in July 2025, an event previously disclosed along with material weaknesses in internal controls and a going concern explanatory paragraph.